Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ACSL1 | P33121 | 2/20 | 0.39 |
| ▸ | ACSL6 | Q9UKU0 | 2/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 8/20 | 0.39 |
| ▸ | MAOA | P21397 | 3/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11841595 | 0.80 | LMNA (0.48) | KDM4EALDH1A1HPGDACSL1ACSL6 | |
| SCHEMBL14262265 | 0.79 | KDM4E (0.44) | SIGMAR1KDM4EALDH1A1HPGDMAOB | |
| SCHEMBL1905327 | 0.77 | KDM4E (0.62) | KDM4EALDH1A1HPGDDYRK1AMAOA | |
| SCHEMBL6469055 | 0.77 | MAOA (0.64) | KDM4EALDH1A1HPGDMAOBMAOA | |
| SCHEMBL4958337 | 0.74 | CA12 (0.54) | KDM4EALDH1A1HPGDMAOBMAOA | |
| SCHEMBL14262263 | 0.74 | CA12 (0.54) | SIGMAR1KDM4EALDH1A1HPGDMAOB | |
| SCHEMBL7029278 | 0.74 | PDE3B (0.54) | KDM4EALDH1A1HPGD | |
| SCHEMBL14262266 | 0.73 | HDAC1 (0.52) | SIGMAR1KDM4EALDH1A1HPGDDYRK1A | |
| SCHEMBL27767737 | 0.72 | MAOB (0.68) | SIGMAR1MAOBMAOABCHEACHE | |
| SCHEMBL30594168 | 0.72 | TSHR (0.62) | KDM4EALDH1A1HPGDDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1814866-A2 | GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006058012-A2 | GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS | WYETH (US) | 2006-06-01 | — | — | WO | disclosed |
| US-20060111355-A1 | Gonadotropin releasing hormone receptor antagonists | WYETH (US) | 2006-05-25 | — | — | US | disclosed |
| WO-2005030131-A2 | BIS-QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | REPLIDYNE, INC (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111355-A1 | Gonadotropin releasing hormone receptor antagonists | GNRHR, LHCGR, GHRHR | SIGMAR1 745/4885KDM4E 3078/4885ALDH1A1 4644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.